20 July 2026 update: the 9mg and 25mg Wegovy tablet strengths have reached the scheduled UK availability milestone. Availability remains provider-specific and should be checked against the current provider route.
GLP-1 Tablet UK Status Tracker
The UK picture is now easier to read when each medicine is checked separately. The Wegovy pill has entered the private-provider market, while Rybelsus remains a diabetes medicine and other oral GLP-1 names remain future-watch topics.
Current position: the Wegovy pill is now listed by UK private providers, with the earliest tablet strengths appearing first. That does not mean every oral GLP-1 medicine is available, every strength is in stock, or that a waitlist is the same as a prescribing route.
Compare current tablet providers
Last reviewed: 12 July 2026. Provider prices and availability can change after a page is checked.
Why status tracking matters
A search for GLP-1 tablets can combine live provider listings, diabetes medicines, clinical trials, overseas approvals and “register interest” pages. Those are different stages. This tracker separates them so a promising headline is not mistaken for a medicine that can be prescribed in the UK today.
UK status at a glance
| Medicine or route | UK position | How to read it |
|---|---|---|
| Wegovy pill | Private listings now visible | Check the provider, strength, stock wording, consultation route and source date. |
| Rybelsus | Established diabetes medicine | Do not treat its diabetes indication as proof of a weight-loss prescribing route. |
| Orforglipron / Foundayo | Future-watch for UK readers | Overseas approval or trial news does not create UK access by itself. |
| Orlistat and Mysimba | Existing non-GLP-1 tablet options | They belong in a separate comparison because they work differently and have different prescribing considerations. |
How to read a provider page
Look for the exact medicine name, route, indication, dose or strength, supply wording, consultation process and last source-check date. “Notify me”, “coming soon”, “pre-order” and “join the waitlist” are useful signals, but they should not be labelled as a normal live price.
Where a provider publishes a standard price, use the medicine-specific comparison to see it beside other providers. Where it publishes only an offer, bundle, subscription or future-status signal, read that context on the provider page rather than treating it as a like-for-like comparison price.
The safest comparison framework
| Check | Good sign | Concern |
|---|---|---|
| UK authorisation | The exact product and indication are supported by a UK source. | Only overseas headlines or trial claims are provided. |
| Medicine identity | Tablet, injection, active ingredient and indication are clearly separated. | Diabetes and weight-loss routes are blended together. |
| Supply status | Live, pre-order, waitlist and out-of-stock wording is explicit. | A registration form is presented as immediate access. |
| Price context | Dose, pack or plan basis and source date are visible. | A headline “from” or first-month price hides the ongoing terms. |
What to do next
If you are comparing a live tablet route, start with the current provider table and then open the provider page for its consultation, delivery and offer conditions. If you are researching a future medicine, use the status wording and official sources rather than assuming that an overseas launch is a UK launch.
Read the oral semaglutide guide for the difference between Wegovy pill listings and Rybelsus, or compare tablets with injections without treating them as interchangeable.
Frequently asked questions
Are GLP-1 tablets available for weight loss in the UK?
Yes, the Wegovy pill is now listed by UK private providers. Availability depends on the provider, exact strength, stock and clinical assessment.
Is Rybelsus a weight-loss version of the Wegovy pill?
No. Rybelsus is oral semaglutide used for type 2 diabetes. Its existence does not prove a general weight-loss prescribing route.
Is a waitlist the same as access?
No. A waitlist, notify-me form or coming-soon label is not the same as a live prescription and fulfilment route.
Can overseas approval affect the UK?
It can signal future direction, but UK licensing, supply and prescribing rules still need to be checked separately.
Does Tablet Compare sell tablets?
No. Tablet Compare provides editorial information and comparisons; prescribing decisions are made through an appropriate clinical service.
Sources and checks
- NICE semaglutide guidance
- NHS semaglutide information
- ASA prescription-only medicine website guidance
- Reviewed for UK authorisation, medicine identity, availability wording and provider-price context on 12 July 2026.
Wegovy pill alert
Get a heads-up when the status changes
We check UK provider pages regularly. If Tablet Compare confirms a provider availability change, we email subscribers.